Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention.
- Author:
Chun YANG
1
;
You-Long LI
;
Jian FANG
;
Xiao ZHANG
;
Hai-Peng LIU
;
Xian-Hui QIN
;
Xi-Ping XU
Author Information
- Publication Type:Journal Article
- MeSH: Adrenergic alpha-Antagonists; therapeutic use; Aged; Amlodipine; therapeutic use; Antihypertensive Agents; therapeutic use; Double-Blind Method; Drug Therapy, Combination; Humans; Hypertension; complications; drug therapy; Male; Middle Aged; Prazosin; analogs & derivatives; therapeutic use; Prospective Studies; Prostatic Hyperplasia; complications; drug therapy; Treatment Outcome; Urinary Retention; complications; drug therapy; Urodynamics; drug effects
- From: National Journal of Andrology 2009;15(5):441-444
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEThis prospective randomized double-blinded clinical trial was designed to explore the effects of amlodipine and the combination of amlodipine with terazosin in improving postvoid residual (PVR) in patients with lower urinary tract symptoms (LUTS) and concomitant hypertension.
METHODSWe randomly divided 360 LUTS patients with concomitant hypertension into a 5 mg amlodipine group, a 2 mg terazosin group and a 5 mg amlodipine plus 2 mg terazosin group, and measured PVR at the baseline and 4 weeks after the treatment.
RESULTSFor male patients with LUTS associate with hypertension, all of amlodipine (APVR = 6.8) , terazosin (APVR = 7. 6), and combination group (APVR = 8.8) can significant reduced the PVR (P < . 0.1), but no significant difference was found among three groups.
CONCLUSIONAmlodipine alone or combined with terazosin can improve the PVR of the LUTS patient effectively, but had no significant difference compared with terazosin.
